

Appl. No. : 10/726,332
Filed : December 2, 2003

REMARKS

Claims 1-28 are pending in the instant application. In response to the Office Action mailed September 15, 2004, Applicants elect to prosecute the claims of Group I, i.e. Claims 1-16 and Claim 19 and new Claims 29-31. The claims of Group I, as noted by the Examiner, are drawn to a human monoclonal antibody to phospholipase A2, classified in class 530, subclass 388.15. Additionally, Applicants further elect, SEQ ID NO: 27 and SEQ ID NO: 28, as the specific immunoglobulin heavy chain sequence and light chain sequence, respectively. Claims 1, 2, 15, 16, 19, and new Claims 29-31 read on the elected species.

Claims 17 and 18 and 20-28, drawn to non-elected processes, have been withdrawn. Claims 1 and 16 have been amended to clarify that the antibody is an isolated antibody or a binding fragment thereof. New Claims 29-31, directed to antibody binding fragments that bind phospholipase A2, have been added. Support for amended Claims 1 and 16, and new Claims 29-31 can be found throughout the specification and claims as originally filed. Support for new Claims 29-31 can be found, for example, at paragraphs [0059], [0066], [0067], and [0068] of the specification.


CONCLUSION

The undersigned has made a good faith effort to respond to the Restriction Requirement. Nevertheless, if any undeveloped issues remain or if any issues require clarification, the Examiner is invited to call the undersigned attorney to resolve such issues promptly. No fees are seen as being necessary for filing this Response. However, the Commissioner is authorized to charge any fees in connection with this paper to Deposit Account No. 11-410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 10/13/06

By: 
Mallary K. de Merlier
Registration No. 51,609
Attorney of Record
Customer No. 20,995
(619) 235-8550